AGORACOM News Flash

AGORACOM Wire - Wednesday February 15th, 2012

Breaking News ....

Lomiko (LMR: TSX-V) to Complete 43-101 Report on Previous Drilling at the Quatre Milles Graphite Property *CLIENT* Read More

Top Sector Stories ....

Strike Graphite Corp. (TSXV:SRK) Acquires Wagon Graphite Project in Quebec in Vicinity of Timcal's Lac des Iles Graphite Mine *CLIENT* Read More | Profile

Strike Graphite goes "Beyond the Press Release"

McLaren Resources (CNSX:MCL) Drills 7.0 Grams Gold Over 7.4 Metres at the TimGinn Property Located Adjacent to the Hollinger Mine *CLIENT* Read More | Watch Beyond the Press Release

DONNER METALS INTERVIEW: David Patterson Discusses the Bracemac-McLeod Mine Development Beyond the Press Release

AGORACOM Launches GraphiteStocksBlog.com

We're proud to announce the launch of GraphiteStocksBlog.com a website dedicated to the needs of investors and companies in the fast growing Graphite industry.

INAUGURAL GRAPHITE SPONSORS

Close

Message: NEWS - Auriga Laboratories First Quarter 2007 Financial Results Conference Call

Reply New Message

Back To Forum Go to List View

AGORACOM-PAULN

Rank: [?]

Treasurer

Points: [?]

477

Rating: [?]

Votes: 0

Currently 0.0/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

NEWS - Auriga Laboratories First Quarter 2007 Financial Results Conference Call

posted on Apr 02, 07 05:01AM

LOS ANGELES, Apr 02, 2007 -- Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of xerostomia, dermatological conditions, and acute respiratory diseases, will hold a conference call on Monday, April 16, 2007 to discuss its first quarter 2007 financial results for the period ended March 31, 2007. The results will be issued in a press release prior to the call on the same day.

Auriga's Founder, Chairman and CEO Philip S. Pesin and CFO Charles R. Bearchell will host the presentation, which will be followed by a question and answer period.

Conference Date: Monday, April 16, 2007
Start Time: 10:00 AM Eastern (7:00 AM Pacific)
Dial-In Number: 1-800-936-9754
International: 1-973-935-2048
Conference ID#: 8607014

Internet Simulcast: http://viavid.net/dce.aspx?sid=00003D0D
(Windows Media Player needed for simulcast)

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization and ask you to wait until the call begins. If you have any difficulty connecting with the conference call, please contact the Liolios Group at 949-574-3860.

A replay of the conference call will be available starting at 1:00 PM Eastern and until midnight, April 30, 2007:

Toll-free replay number: 1-877-519-4471 International replay number: 1-973-341-3080 Replay Pin Number: 8607014

About Auriga Laboratories(TM)

Auriga Laboratories is a specialty pharmaceutical company building an industry changing commission based-sales model. The company's high-growth business model combines driving revenues through a variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which is designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral(TM) for the treatment of xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), Extendryl(R), and Levall(R) families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.

Auriga Laboratories, Inc.
Andrew D. Shales, Chief Operating Officer,
678-282-1613 Fax: 678-282-1683
ashales@aurigalabs.com or

Liolios Group, Inc.
Investor Relations:
Ron Both or Geoffrey Plank,
949-574-3860
ron@liolios.com